Cytotoxic therapy for prostate cancer

Por I. G. Rusakov, S. V. Mishugin
Publicado em 2018-11-01

Cost-effectiveness of abiraterone treatment in patients with castration-resistant prostate cancer who previously received docetaxel therapy

Por A. V. Rudakova, D. O. Meshkov, S. V. Mishugin
Publicado em 2014-09-01

DEVELOPMENT AND CLINICAL EFFECTIVENESS OF ANTIANDROGENS IN THE TREATMENT OF ADVANCED PROSTATE CANCER

Por S. V. MISHUGIN, A. A. GRITSKEVICH, I. G. RUSAKOV
Publicado em 2016-12-01

POSSIBILITIES OF A COMBINATION OF DOCETAXEL WITH ANDROGEN DEPRIVATION IN INITIAL THERAPY OF HORMONESENSITIVE PROSTATE CANCER

Por A. A. GRITSKEVICH, S. V. MISHUGIN, I. G. RUSAKOV
Publicado em 2017-06-01

THE PLACE OF ENZALUTAMIDE IN THE SERIAL TREATMENT OF TREATMENT-RESISTANT PROSTATE CANCER

Por A. A. GRITSKEVICH, S. V. MISHUGIN, I. G. RUSAKOV
Publicado em 2017-06-01

POSSIBILITIES OF RADIUM-223 APPLICATION IN THERAPY OF PROSTATE GLAND CANCER

Por A. A. GRITSKEVICH, S. V. MISHUGIN, I. G. RUSAKOV
Publicado em 2017-06-01

Cost-effectiveness of abiraterone treatment in patients with castration-resistant prostate cancer who previously received docetaxel therapy

Por A. V. Rudakova, D. O. Meshkov, S. V. Mishugin
Publicado em 2014-11-01

Mesto khimioterapii i gormonoterapii vo 2-y linii lecheniya kastratsionno-rezistentnogo raka predstatel'noy zhelezy

Por I G Rusakov, A A Gritskevich, S V Mishugin
Publicado em 2012-09-01

Еfficiacy and safety of radium-223 in the treatment of metastatic castration-resistant prostate cancer

Por I. G. Rusakov, A. A. Gritskevich, T. P. Baitman, S. V. Mishugin
Publicado em 2020-12-01

The castration level of testosterone and hormonal resistance of prostate cancer in androgen deprivation therapy

Por I. G. Rusakov, A. A. Gritskevich, T. P. Baitman, S. V. Mishugin
Publicado em 2020-12-01

TAXANES IN THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER

Por T. N. Skvortsova, S. V. Mishugin, A. A. Gritskevich, I. G. Rusakov
Publicado em 2017-01-01

The new approaches to the treatment of castration- resistant prostate cancer: PARP inhibitors

Por А. А. Gritskevich, I. G. Rusakov, Т. Р. Baitman, S. V. Mishugin
Publicado em 2021-06-01

Study of the economic efficiency of the combined method of Octreotide-depo + dexamethasone therapy in the treatment of patients with castration-resistant prostate cancer

Por S. V. Mishugin, I. G. Rusakov, I. V. Novikova, A. A. Gritskevich
Publicado em 2019-06-01

CLINICAL ASSESSMENT OF TAXANES IN THE FIRST-LINE CYTOTOXIC THERAPY OF CASTRATION-RESISTANT PROSTATE CANCER

Por A. A. GRITSKEVICH, S. V. MISHUGIN, A. A. TEPLOV, I. G. RUSAKOV
Publicado em 2016-12-01

EVALUATION OF EFFECT OF PROLONGED ACTION SOMATOSTATIN ANALOGUE – OCREOTIDE-DEPO – ON THE FOLLOWING HORMONAL AND CYTOTOXIC THERAPY IN PATIENTS WITH METASTATIC CASTRATE-RESIS...

Por S. V. Mishugin, A. A. Gritskevich, A. A. Mordovin, I. G. Rusakov
Publicado em 2017-11-01

The role of sunitinib in the therapy of metastatic renal cell carcinoma

Por I. G. Rusakov, A. A. Gritskevich, T. P. Baitman, A. N. Shipilova, S. V. Mishugin
Publicado em 2020-07-01

Effective suppression of testosterone: the best castration therapy for hormone-sensitive prostate cancer?

Por A. A. Gritskevich, S. V. Mishugin, A. A. Teplov, V. L. Medvedev, I. G. Rusakov
Publicado em 2015-12-01

The role of prostate-specific antigen in the prediction of hormone-sensitive prostate cancer

Por A. A. Gritskevich, S. V. Mishugin, A. A. Teplov, V. L. Medvedev, I. G. Rusakov
Publicado em 2015-12-01

EVALUATION OF EFFICACY OF BUSERELIN-DEPO IN PATIENTS WITH LOCALLY ADVANCED AND METHASTATIC PROSTATE CANCER

Por S. V. MISHUGIN, A. A. DROBYAZKO, A. A. MORDOVIN, A. A. GRICKEVICH, I. G. RUSAKOV
Publicado em 2017-06-01

The role of Buserelin in the treatment of advanced prostate cancer (APC)

Por S. V. Mishugin, A. A. Drobyazko, A. A. Mordovin, A. A. Gritskevich, I. G. Rusakov
Publicado em 2015-12-01